Publications by authors named "Andrew Koff"

Claim this Profile
T
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.
Evan Rosenbaum, Rodrigo Gularte-Mérida, Evan Seffar, Jasme Lee, Mathew Adamow, Andrew Koff

Cancer Res Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell cycle dysregulation in cancer.
Antonino Glaviano, Samarendra K Singh, E Hui Clarissa Lee, Elena Okina, Hiu Yan Lam, Andrew Koff

Pharmacol Rev· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R Dry, Andrew Koff

Cancer Cell· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
Rei Kudo, Anton Safonov, Catherine Jones, Enrico Moiso, Jonathan R Dry, Andrew Koff

Cancer Cell· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.
Kamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, Sameer Bhargava, Andliena Tahiri, Andrew Koff

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma.
Caroline E Gleason, Mark A Dickson, Mary E Klein Dooley, Cristina R Antonescu, Rodrigo Gularte-Mérida, Andrew Koff

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma.
Sandra P D'Angelo, Allison L Richards, Anthony P Conley, Hyung Jun Woo, Mark A Dickson, Andrew Koff

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.
Qing Li, Baishan Jiang, Jiaye Guo, Hong Shao, Isabella S Del Priore, Andrew Koff

Cancer Discov· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A549 in-silico 1.0: A first computational model to simulate cell cycle dependent ion current modulation in the human lung adenocarcinoma.
Sonja Langthaler, Theresa Rienmüller, Susanne Scheruebel, Brigitte Pelzmann, Niroj Shrestha, Andrew Koff

PLoS Comput Biol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.
Mary E Klein, Mark A Dickson, Cristina Antonescu, Li-Xuan Qin, Scott J Dooley, Andrew Koff

Oncogene· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Mary E Klein, Marta Kovatcheva, Lara E Davis, William D Tap, Andrew Koff

Cancer Cell· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.
Marta Kovatcheva, Mary E Klein, William D Tap, Andrew Koff

Mol Cell Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATRX is a regulator of therapy induced senescence in human cells.
Marta Kovatcheva, Will Liao, Mary E Klein, Nicolas Robine, Heather Geiger, Andrew Koff

Nat Commun· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Mark A Dickson, Gary K Schwartz, Mary Louise Keohan, Sandra P D'Angelo, Mrinal M Gounder, Andrew Koff

JAMA Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of molecular biology to individualize therapy for patients with liposarcoma.
Gulam Abbas Manji, Samuel Singer, Andrew Koff, Gary K Schwartz

Am Soc Clin Oncol Educ Book· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.
Marta Kovatcheva, David D Liu, Mark A Dickson, Mary E Klein, Rachael O'Connor, Andrew Koff

Oncotarget· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ability of TRIM3 to induce growth arrest depends on RING-dependent E3 ligase activity.
Radhika Raheja, Yuhui Liu, Ellen Hukkelhoven, Nancy Yeh, Andrew Koff

Biochem J· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyrosine phosphorylation of the p21 cyclin-dependent kinase inhibitor facilitates the development of proneural glioma.
Ellen Hukkelhoven, Yuhui Liu, Nancy Yeh, Daniel Ciznadija, Stacy W Blain, Andrew Koff

J Biol Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer.
Sergio Marchini, Elizabeth Poynor, Richard R Barakat, Luca Clivio, Michela Cinquini, Andrew Koff

Clin Cancer Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p27kip1 protein levels reflect a nexus of oncogenic signaling during cell transformation.
Jeffrey P Miller, Nancy Yeh, Christoph P Hofstetter, Doruk Keskin, Andrew S Goldstein, Andrew Koff

J Biol Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma.
Daniel Ciznadija, Yuhui Liu, Stephanie M Pyonteck, Eric C Holland, Andrew Koff

Cancer Res· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hdm2- and proteasome-dependent turnover limits p21 accumulation during S phase.
Daniel Ciznadija, Xin-Hua Zhu, Andrew Koff

Cell Cycle· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZIC1 overexpression is oncogenic in liposarcoma.
Elliott Brill, Ryan Gobble, Christina Angeles, Mariana Lagos-Quintana, Aimee Crago, Andrew Koff

Cancer Res· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior.
Yan Liu, Shannon E Elf, Takashi Asai, Yasuhiko Miyata, Yuhui Liu, Andrew Koff

Cell Cycle· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis.
Liren Liu, Sharrell Lee, Jianxuan Zhang, Sara B Peters, Jeffrey Hannah, Andrew Koff

Mol Cell· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis